

CLAIMS

1. A pharmaceutical composition for eliminating or reducing the number of unwanted CD3 and/or CD7 positive cells, comprising a mixture of at least a first molecule specifically recognizing CD3 or CD7 and at least a second molecule specifically recognizing another ligand receptor associated with the surface of such an unwanted cell, whereby at least one of the specifically recognizing molecules is provided with a toxic moiety.
2. A pharmaceutical composition according to claim 1, whereby said first molecule specifically recognizes CD3 and said second molecule specifically recognizes CD7.
3. A pharmaceutical composition according to claim 1 or 2, wherein said first molecule is an antibody, or a fragment or a derivative thereof.
4. A pharmaceutical composition according to any one of claims 1-3, wherein said second molecule is an antibody, or a fragment or a derivative thereof.
5. A pharmaceutical composition according to any one of claims 1-4, wherein said toxic moiety is ricin.
6. A pharmaceutical composition according to any one of claim 5, wherein ricin is deglycosylated ricin A.
7. A pharmaceutical composition according to any one of claims 1-6, wherein said toxic moiety is chemically linked to said molecule specifically recognizing CD3, CD7 or another ligand receptor associated with the surface of such an unwanted cell.
8. A pharmaceutical composition according to any one of claims 1-7, wherein at least two molecules specifically recognizing different receptors are provided with toxic moieties, which may be the same or different toxic moieties.
9. A pharmaceutical composition according to any one of claims 1-8, further comprising at least one further molecule

specifically recognizing CD5, CD2, CD4, CD8 or an IL-2 receptor.

10. A pharmaceutical composition according to claim 1, wherein said first molecule is a gamma2B IgG antibody or a derivative thereof, which recognizes CD3.

11. A pharmaceutical composition according to anyone of the afore going claims, which comprises at least the equivalent dosis of 25 micrograms of Ricin A per square meter of body surface.

12. A pharmaceutical composition according to claim 11, comprising at least the equivalent dosis of 100 micrograms of Ricin A per square meter of body surface.

13. A pharmaceutical composition comprising at most the equivalent dosis of 25 mg of Ricin A per square meter of body surface.

14. A composition according to anyone of the afore going claims for use as a pharmaceutical.

15. Use of a composition according to anyone of the afore going claims in the preparation of a medicament for the treatment of Graft vs. Host disease, Graft rejections, T-cell leukemias, T-cell lymphomas or other CD3 and/or CD7 positive malignancies, autoimmune diseases or infectious immune diseases such as HIV-infection.

16. A kit of pharmaceutical compositions for treating Graft vs. Host disease and/or graft rejection comprising a composition according to anyone of claims 1-14 and a pharmaceutical composition comprising at least one corticosteroid.

17. A kit according to claim 16 for use as a pharmaceutical.

Add A3

B8